• Vaccine Name: rBCGpMV361-TgCyP
• Target Pathogen: Toxoplasma gondii
• Target Disease: Toxoplasmosis
• Vaccine Ontology ID: VO_0004656
• Type: Recombinant vector vaccine
• Status: Research
• Host Species for Licensed Use: None
• Host Species as Laboratory Animal Model: mouse
• CyP gene engineering:
  • Type: Recombinant vector construction
  • Description:
  • Detailed Gene Information: Click Here.
• Vector:
  • Vector name:
  • VO vector ID: VO_0001023
• Preparation: Following amplification of the T. gondii cyclophilin gene, the shuttle expression plasmid pMV261-TgCyP and integrative expression plasmid pMV361-TgCyP were constructed, and their expression was stimulated after transfection into BCG (Yu et al., 2013).
• Immunization Route: Intramuscular injection (i.m.)

Mouse Response

• Vaccination Protocol: rBCGpMV261-TgCyP and rBCGpMV361-TgCyP (106 CFU) were used to immunise the mice in two different manners (through an i.v. or oral route) (Yu et al., 2013).
• Vaccine Immune Response Type: VO_0003057
• Challenge Protocol: Two weeks after the third vaccination, mice were selected randomly from each group and challenged intraperitoneally (i.p.) with 10^3 highly virulent T. gondii RH strain tachyzoites (Yu et al., 2013).
• Efficacy: The levels of Th1-type IFN-γ, IL-2 and IL-12 were significantly increased following immunisation with the rBCG vaccines via the i.v. or oral route, which indicated that catalytic activity against T. gondii infection was generated in the mice. rBCGpMV361-TgCyP i.v. inoculation resulted in a higher protection efficiency, as demonstrated by the increased survival time and survival rate (17%) of BALB/c mice (Yu et al., 2013).